Sabrina Johnson is the founder, President, and CEO of Daré Bioscience, a NASDAQ-listed biopharmaceutical company advancing innovative therapies in women's reproductive health—spanning contraception, vaginal health, sexual health, and fertility—built on a guiding principle she calls "biotechnology for women, by women."
Before founding Daré in 2015, Sabrina spent over thirteen years as COO and CFO at Cypress Bioscience, leading four product launches, building a 115-person commercial organization, and raising $170 million for a pipeline that included Savella for fibromyalgia. She then served as COO and CFO at WomanCare Global International—delivering reproductive health products to women in more than 100 countries—before becoming CFO and CAO at Calibr, the California Institute for Biomedical Research.
At Daré Bioscience, Sabrina leads a lean team of twenty-five executing what she calls the "groomed trail" approach—identifying therapeutic gaps in women's health, matching them to existing FDA-approved actives, and closing the distance between promising science and something a woman can actually use. With a first-in-category non-hormonal contraceptive in a pivotal Phase 3, a sildenafil cream for female arousal disorder launching in 2026, and over $75 million in non-dilutive funding from the Gates Foundation, NIH, and ARPA-H—Sabrina's journey from Rome-born biomedical engineer who nearly pursued the arts, to NASDAQ CEO, shows what it looks like when you choose your mission before your industry and refuse to treat women's health as a niche
.png)